J
Jose Alvir
Researcher at Pfizer
Publications - 165
Citations - 16027
Jose Alvir is an academic researcher from Pfizer. The author has contributed to research in topics: Schizophrenia & Tardive dyskinesia. The author has an hindex of 56, co-authored 146 publications receiving 15289 citations. Previous affiliations of Jose Alvir include New York University & Long Island Jewish Medical Center.
Papers
More filters
Journal ArticleDOI
Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.
Delbert Robinson,Margaret G. Woerner,Jose Alvir,Robert M. Bilder,Robert Goldman,Stephen Geisler,A. Koreen,Brian B. Sheitman,Miranda Chakos,David Mayerhoff,Jeffrey A. Lieberman +10 more
TL;DR: There is a high rate of relapse within 5 years of recovery from a first episode of schizophrenia and schizoaffective disorder, and this risk is diminished by maintenance antipsychotic drug treatment.
Journal ArticleDOI
Duration of psychosis and outcome in first-episode schizophrenia.
Antony Loebel,Jeffrey A. Lieberman,Jose Alvir,David Mayerhoff,Stephen Geisler,Sally Szymanski +5 more
TL;DR: Duration of psychosis before treatment may be an important predictor of outcome in first-episode schizophrenia, and is significantly associated with time to remission as well as with level of remission.
Journal ArticleDOI
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States
TL;DR: The increasing risk of agranulocytosis with age and the reduced incidence after the first six months of treatment provide additional guidelines for the prescription and monitoring of clozapine treatment in the future.
Journal ArticleDOI
Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset
Nancy S. Wexler,Judith Lorimer,Julie Porter,Fidela Gomez,Carol Moskowitz,Edith Shackell,Karen Marder,Penchaszadeh Gk,Simone A. Roberts,Javier Gayán,Denise Brocklebank,Stacey S. Cherny,Lon R. Cardon,Jacqueline Gray,Stephen R. Dlouhy,Sandra Wiktorski,Marion E. Hodes,P. Michael Conneally,J. B. Penney,James F. Gusella,Jang Ho Cha,Michael C. Irizarry,Diana Rosas,Steven M. Hersch,Zane R. Hollingsworth,Marcy E. MacDonald,Anne B. Young,J. Michael Andresen,David E. Housman,Margot de Young,Ernesto Bonilla,Theresa Stillings,Américo Negrette,S. Robert Snodgrass,Maria Dolores Martinez-Jaurrieta,Maria A. Ramos-Arroyo,Jacqueline Bickham,Juan Sanchez Ramos,Frederick J. Marshall,Ira Shoulson,Gustavo Rey,Andrew Feigin,Norman Arnheim,Amarilis Acevedo-Cruz,Leticia Acosta,Jose Alvir,Kenneth H. Fischbeck,Leslie M. Thompson,Angela Young,Leon S. Dure,Christopher J. O'Brien,Jane S. Paulsen,Adam M. Brickman,Denise Krch,Shelley Peery,Penelope Hogarth,Donald S. Higgins,Bernhard Landwehrmeyeri +57 more
TL;DR: A model estimated the components of additive genetic, shared environment, and nonshared environment variances confirming that approximately 40% of the variance remaining in onset age is attributable to genes other than the HD gene and 60% is environmental.
Journal ArticleDOI
Provocative tests with psychostimulant drugs in schizophrenia.
TL;DR: The results suggest the presence of a subgroup of schizophrenic patients who exhibit psychotic symptom activation with PS in a state dependent or independent fashion and this biologic phenomenon may be clinically exploitable and should be investigated further.